The hormonally active form of vitamin D 3 , 1,25(OH) 2 D 3 , inhibits the proliferation and induces the differentiation of normal and leukemic myeloid cells. 1 The synthesis of 1,25(OH) 2 D 3 begins with the production of vitamin D 3 (cholecalciferol) after 7-dehydrocholesterol in the skin is exposed to ultraviolet radiation (wavelength 290-315 nm). To become biologically active, vitamin D undergoes two hydroxylations: the first in the liver, forming 25-hydroxyvitamin D (25(OH)D), the prohormone and major circulating form of vitamin D; the second at the 1 a position, forming 1,25(OH) 2 2 who used 266 mg 25(OH)D 3 3 times a week in five patients. Three patients remained stable and one showed a major response. We hypothesized that by providing ample supply of cholecalciferol, the 'pre-prohormone', we might alter the phenotype of low-risk MDS.
We conducted an open-label clinical trial in patients with low-and intermediate-1-(INT-1) risk MDS with oral 2000-4000 IU cholecalciferol (vitamin D 3 ) daily for up to 12 months. The primary outcome was hematological improvement as defined by the revised International Working Group criteria. Secondary outcomes were toxicity, serum levels of 25(OH)D and quality of life (QOL) as measured by the Functional Assessment of Cancer Therapy, General Measures (FACT-G) and Functional Assessment of Chronic Illness Therapy, Fatigue Scale (FACIT-F) scales.
Patients with the diagnosis of MDS were eligible if the International Prognostic Scoring System (IPSS) score was 0-1.0 at the time of enrollment. Bone marrow aspirate and biopsy with karyotyping was performed within 12 weeks of initiation of therapy. Patients with a history of hypercalcemia were excluded. Serum ferritin X50 ng/ml, normal serum vitamin B 12 and folate levels were required. Patients continued supportive care measures such as red cell and platelet transfusions. Patients were required to have no therapy for MDS for 28 days before enrollment and to have no vitamin D supplements within 6 weeks of enrollment.
Patients received 2000 IU (50 mg) of vitamin D 3 (cholecalciferol) once daily, orally, for 6 months. The dose was then increased to 4000 IU (100 mg) once daily for an additional 6 months. We used tablets containing 1000 IU cholecalciferol manufactured by Natural Factors (Burnaby, BC, Canada). We verified the vitamin D 3 content of four randomly selected tablets using high-pressure liquid chromatography, and confirmed it to be accurate (1031770 IU). Toxicity was monitored monthly by measuring serum calcium, phosphorus and creatinine. Serum 25(OH)D levels, which reflect vitamin D stores, were measured at baseline and monthly by a competitive protein binding assay using rat vitamin D-binding protein. 3 Hematological response was assessed every 3 months. QOL was measured at baseline and every 3 months using FACT-G (version 4) and FACIT-F (version 4). Mixed model regression was used to account for correlation between time points within individuals. In addition to fixed intercept and slope terms, random intercept and slope terms were included to allow individuals to have different pretreatment levels of vitamin D and different underlying response propensities.
Twenty-six patients were enrolled between July 2003 and October 2004. Patient characteristics are shown in Table 1 . The median age was 66 years (range 52-94). Eighteen patients were male and eight were female. The median time to treatment from diagnosis was 8 months (range 0-79 months). Twelve patients had no prior therapy for MDS. The drug was well tolerated. No grade 3 or 4 toxicity was observed, and only one patient discontinued vitamin D 3 owing to a side effect (grade 2 nausea). Hypercalcemia (serum calcium 410.3 mg/dl) was observed in one patient. Hyperphosphatemia (serum phosphorus 44.5 mg/dl) was noted in seven patients. Patient no. 13 had elevated phosphorus at baseline (4.8 mg/dl); subsequent phosphorus levels were normal. Three patients had chronic kidney disease, which is likely responsible for the hyperphosphatemia. Two patients (patients no. 14 and no. 17) had no alternative explanation for their hyperphosphatemia. Patient no. 23 had baseline-corrected serum calcium of 10.3 mg/dl, which rose to 10.9 mg/dl after 4 months of cholecalciferol at 2000 IU/day. This patient was eventually diagnosed with multiple myeloma and was removed from therapy.
Four patients died while on study. These deaths were considered by the investigators to be unrelated to vitamin D 3 . Patient no. 2 died from cardiac failure owing to hemosiderosis. Patient no. 12, who had a history of congestive heart failure, died from cardiopulmonary arrest 1 month after finishing the study medication. Patient no. 13 died from disseminated mucormycosis. Patient no. 15 died suddenly after 5 months of therapy. He had a history of diabetes mellitus type II, coronary artery bypass, chronic renal failure and congestive heart failure. Of these four, patients no. 2 and no. 15 were noted with elevated corrected serum calcium or serum phosphorus during the study and both suffered from cardiomyopathy and chronic renal failure.
Twenty-three patients were available for response assessment. Three were ineligible (diagnosis revised to non-Hodgkin's lymphoma in patient no. 3; patient no. 8 took drug only for 15 days, then discontinued it owing to nausea; patient no. 9 mistakenly took erythropoietin concurrently). The median time of therapy was 149 days (range 15-368 days). Four patients finished the entire 12 months of therapy and an additional eight took 4000 IU vitamin D 3 for at least 1 month after the initial 6 14) . The mean 25(OH)D at baseline was 37716 ng/ml (range 10-74 ng/ml). The reference range for this assay is 20-100 ng/ ml. The physiologically normal range for 25(OH)D is a matter of debate, but levels o20 ng/ml generally are considered as vitamin D deficiency. Serum 25(OH)D levels rose 2.3 ng/ml per month. The total mean FACT-G score was 83.6727. The mean score for the fatigue subscale was 34.4715. There was a nonsignificant improvement in the FACT-G total score (P ¼ 0.11). When the time from baseline was treated as a continuous variable, the estimated change per month was 0.47 (95% confidence interval À0.11 to 1.06). This improvement was entirely because of a significant change in the emotional well-being (EWB) subscale (P ¼ 0.0007), with no change in the physical (P ¼ 0.84), social (P ¼ 0.97) and functional (P ¼ 0.41) subscales. The improvement in the EWB score occurred mostly between baseline and 6 months ( Figure 1) .
The overall FACT score at baseline, 83.6727 (n ¼ 26), was comparable to the reported norm for cancer patients (80.9717, n ¼ 2236). 4 Transfusion-dependent individuals had a lower baseline FACT score (75.2716, n ¼ 12). Conversely, the overall QOL at baseline for nontransfusion-dependent patients was high (FACT-G score of 92.4713, n ¼ 13). At baseline, the score on the EWB subscale was comparable to the reported norm for cancer patients (18 and 18.7, respectively). The EWB score rose throughout the study in both transfusion-dependent and transfusion-independent patients. Notably, the improvements in the EWB score paralleled the increases in serum 25(OH)D levels ( Figure 1) .
Oral cholecalciferol (vitamin D 3 ) 50-100 mg (2000-4000 IU)/ day did not result in hematological responses in patients with low-and INT-1-risk MDS. To examine whether this intervention might have retarded the progression of MDS, we compared the median survival of our patients from the time of diagnosis to the median survival of MDS patients in the IPSS cohort. The IPSS cohort consists of 267 low-risk (IPSS score ¼ 0) and 314 INT-1 risk (IPSS score 0.5-1.0) untreated MDS patients. Our treatment did not appear to change the natural history of MDS as the median survival of both low-and INT-1-risk group in our study (5.1 and 3.1 years) was similar to the median survival of the IPSS cohort (5.7 and 3.5 years in the low-and INT-1-risk groups).
What is the explanation for the lack of effect of daily cholecalciferol in MDS? One possibility is that pharmacological doses of cholecalciferol, a natural pre-prohormone of 1,25(OH) 2 D 3 , will not result in the beneficial cell regulatory effects of the active hormone, despite providing adequate amounts of 25(OH)D 3 for local conversion to 1,25(OH) 2 D 3 . Alternately, the dosage may have been too low to achieve these effects. The therapeutic window of cholecalciferol has not been fully tested. However, doses up to 10 000 IU vitamin D 3 per day are considered by many authorities (e.g., Vieth) to be safe.
The high baseline score on the FACT-G scale in our patients was surprising, as the QOL of these patients was not markedly different from the normative data of the general US adult population. As expected, the QOL scores for 12 transfusiondependent patients were lower. The high baseline FACT-G score in nontransfusion-dependent patients underlies the importance of developing nontoxic treatment approaches for these patients. We expected that QOL might decline given that there was no hematological improvement. However, the overall QOL scores improved owing to a significant improvement in EWB. Recent psychometric studies have shown that a two-point scale difference on the FACT-G subscale and a five-point difference on the FACT-G total score are associated with meaningful differences on clinical indicators. 5 These benchmarks suggest that the changes observed in this study are clinically important.
Several factors could account for the improved QOL in our patients, including the fact that the sicker patients dropped out of the study leaving the healthier ones to respond to the questionnaire (i.e., survival bias). To examine this possibility, we analyzed the differences between patients who finished at least 6 months of vitamin D (n ¼ 13, 'completers') and those who did not (n ¼ 12, 'noncompleters'). There were slightly more transfusion-dependent patients (7/12) among the noncompleters than among the completers (5/13). Moreover, the three patients with an IPSS score of 1.0 were in the group that did not complete more than 6 months. However, there was no difference between the baseline FACT-G scores (84715.5 and 84719) and EWB subscore (17.874 and 18.174) in these two groups, suggesting that the observed emotional improvement was not owing to the selective elimination of sicker patients. Furthermore, the fact that the overall FACT-G score remained stable, and only the EWB scale improved, suggests that the improved EWB may be a treatment effect. Figure 1 illustrates the change in EWB relative to serum 25(OH)D. These data illustrate that the EWB subscores paralleled the rise in serum 25(OH)D levels. These data are Letters to the Editor unlike those commonly observed for placebo effects, as placebo effects often wane as treatment time increases. The observation that vitamin D improves mood is consistent with several prior studies. [6] [7] [8] For example, Jorde et al. 6 reported that a low serum level of 25(OH)D among participants in the fifth Tromsø study in northern Norway was significantly associated with psychological depression. Lansdowne and Provost 7 found that supplementation with cholecalciferol (400-800 IU/day) for 5 days during late winter resulted in a significantly enhanced positive affect. Similarly, Vieth et al. 8 found improved well-being after vitamin D 3 supplementation for 3 months.
In summary, oral cholecalciferol (vitamin D 3 ) at a dose of 50-100 mg/day did not result in hematological improvements in low-and INT-1-risk MDS patients, despite significant increases in 25(OH)D levels. This drug was well tolerated at these doses. Our study suggests that cholecalciferol (vitamin D 3 ) has a significant positive effect on mood. Given the low toxicity and low cost of oral cholecalciferol, further dose escalations appear warranted.
